Urine Trypsinogen 2 as a Diagnostic Marker for Acute Pancreatitis: A Prospective Study

Abstract

Background: Acute pancreatitis presents diagnostic challenges due to its diverse clinical presentation and limitations of traditional serum biomarkers. This study explores the diagnostic potential of urine trypsinogen 2 in acute pancreatitis, an area relatively unexplored in our institution. Methods: A prospective study involving 96 patients admitted between December 2020 and June 2022 with symptoms suggestive of pancreatitis was conducted. Urine trypsinogen 2 levels were quantitatively assessed alongside serum amylase and lipase. Radiological investigations were employed when necessary. The final diagnosis integrated clinical, biochemical, and radiological findings. Results: Urine trypsinogen 2 exhibited a sensitivity of 88.4% and a specificity of 91.7%, outperforming serum amylase and approaching serum lipase. Comparative analysis revealed significant advantages of urine trypsinogen 2 in sensitivity, specificity, and predictive values. Conclusion: Urine trypsinogen 2 emerges as a non-invasive, accurate, and early diagnostic marker for acute pancreatitis, with the potential to enhance diagnostic precision and improve patient outcomes. Further validation in diverse clinical settings is warranted